Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model
- 9 November 2015
- journal article
- research article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 23 (1) , 53-63
Abstract
Compelling epidemiologic studies indicate that obesity is a risk factor for many human cancers, including thyroid cancer. In recent decades, the incidence of thyroid cancer has dramatically increased along with a marked rise in obesity prevalence. We previously demonstrated that a high fat diet (HFD) effectively induced the obese phenotype in a mouse model of thyroid cancer (ThrbPV/PVPten+/− mice). Moreover, HFD activates the STAT3 signal pathway to promote more aggressive tumor phenotypes. The aim of the present study was to evaluate the effect of S3I-201, a specific inhibitor of STAT3 activity, on HFD-induced aggressive cancer progression in the mouse model of thyroid cancer. WT and ThrbPV/PVPten+/− mice were treated with HFD together with S3I-201 or vehicle-only as controls. We assessed the effects of S3I-201 on HFD-induced thyroid cancer progression, the leptin-JAK2-STAT3 signaling pathway, and key regulators of epithelial-mesenchymal transition (EMT). S3I-201 effectively inhibited HFD-induced aberrant activation of STAT3 and its downstream targets to markedly inhibit thyroid tumor growth and to prolong survival. Decreased protein levels of cyclins D1 and B1, cyclin dependent kinase 4 (CDK4), CDK6, and phosphorylated retinoblastoma protein led to the inhibition of tumor cell proliferation in S3I-201-treated ThrbPV/PVPten+/− mice. Reduced occurrence of vascular invasion and blocking of anaplasia and lung metastasis in thyroid tumors of S3I-201-treated ThrbPV/PVPten+/− mice were mediated via decreased expression of vimentin and matrix metalloproteinases, two key effectors of EMT. The present findings suggest that inhibition of the STAT3 activity would be a novel treatment strategy for obesity-induced thyroid cancer.Keywords
This publication has 48 references indexed in Scilit:
- Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenograftsProceedings of the National Academy of Sciences, 2012
- Roles of STAT3 and ZEB1 Proteins in E-cadherin Down-regulation and Human Colorectal Cancer Epithelial-Mesenchymal TransitionJournal of Biological Chemistry, 2012
- Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesisProceedings of the National Academy of Sciences, 2011
- Diabetes and Thyroid Cancer Risk in the National Institutes of Health-AARP Diet and Health StudyThyroid®, 2011
- Nonradiation Risk Factors for Thyroid Cancer in the US Radiologic Technologists StudyAmerican Journal of Epidemiology, 2009
- PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancerOncogene, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activityProceedings of the National Academy of Sciences, 2007
- Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasisOncogene, 2004
- STATs in oncogenesisOncogene, 2000